Effects of activation of μ-, κ1-, δ1-, δ2-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusion

Yu B. Lishmanov, L. N. Maslov, E. I. Barzakh, A. V. Krylatov, P. R. Oltgen, S. A. Browne, M. Govindashvami

Research output: Contribution to journalArticle

Abstract

Different subtypes of opioid receptors (OR) were activated in rats in vivo to study the activation effect on the heart's resistance to ischemia and reperfusion. It has been established that administration of deltorphin II, a selective δ2-OR agonist, lowered the infarct size/area at risk index (IS/AAR) by 23%. Naltrexone, naloxone methiodide (an OR inhibitor not penetrating the blood-brain barrier (BBB)), and naltriben (δ2-antagonist) eliminated the cardioprotective effect of deltorphin II, while BNTX (a δ1-antagonist) produced no effect on the cardioprotective action of the δ2-agonist. The infarct-reducing effect of deltorphin II was eliminated by administration of chelerythrine (a protein kinase C (PKC) inhibitor), glibenclamide (a KATP-channels inhibitor), and 5-hydroxydecanoate (a mitochondrial KATP-channel blocker). Administration of other opioids did not reduce the IS/AAR index. It has been established that all the deltorphins manifest antiarrhythmic potency. Other opioids do not produce any effect on the incidence of arrhythmia occurrences. The antiarrhythmic effect of deltorphin II was eliminated by preliminary administration of naltrexone, naloxone methiodide, and naltriben, but BNTX did not affect the δ2-agonist's anti-arrhythmic effect. The preliminary administration of chelerythrine, a PKC inhibitor, eliminated the δ2 agonist's antiarrhythmic action. However, glibenclamide and 5-hydroxydecanoate did not alter the antiarrhythmic effect by deltorphin II. Therefore, activation of the peripheral δ2-ORs reduces the infarct size and prevents the onset of arrhythmias. The antiarrhythmic effect of the δ2-OR stimulation is mediated by activating PKC and opening the mitochondrial KATP-channels. PKC participates in the antiarrhythmic effect of the δ2-OR activation, but this effect does not depend on the condition of KATP-channels.

Original languageEnglish
Pages (from-to)354-362
Number of pages9
JournalBiology Bulletin
Volume36
Issue number4
DOIs
Publication statusPublished - 1 Jul 2009

Fingerprint

narcotics
Opioid Receptors
ischemia
Reperfusion
Ischemia
Chemical activation
heart
Protein Kinase C
infarction
protein kinase C
receptors
agonists
KATP Channels
Naltrexone
Protein C Inhibitor
Glyburide
Protein Kinase Inhibitors
glibenclamide
Opioid Analgesics
naloxone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Effects of activation of μ-, κ1-, δ1-, δ2-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusion. / Lishmanov, Yu B.; Maslov, L. N.; Barzakh, E. I.; Krylatov, A. V.; Oltgen, P. R.; Browne, S. A.; Govindashvami, M.

In: Biology Bulletin, Vol. 36, No. 4, 01.07.2009, p. 354-362.

Research output: Contribution to journalArticle

Lishmanov, Yu B. ; Maslov, L. N. ; Barzakh, E. I. ; Krylatov, A. V. ; Oltgen, P. R. ; Browne, S. A. ; Govindashvami, M. / Effects of activation of μ-, κ1-, δ1-, δ2-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusion. In: Biology Bulletin. 2009 ; Vol. 36, No. 4. pp. 354-362.
@article{2bf7ea8b819a4faeb2265b52f309dca9,
title = "Effects of activation of μ-, κ1-, δ1-, δ2-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusion",
abstract = "Different subtypes of opioid receptors (OR) were activated in rats in vivo to study the activation effect on the heart's resistance to ischemia and reperfusion. It has been established that administration of deltorphin II, a selective δ2-OR agonist, lowered the infarct size/area at risk index (IS/AAR) by 23{\%}. Naltrexone, naloxone methiodide (an OR inhibitor not penetrating the blood-brain barrier (BBB)), and naltriben (δ2-antagonist) eliminated the cardioprotective effect of deltorphin II, while BNTX (a δ1-antagonist) produced no effect on the cardioprotective action of the δ2-agonist. The infarct-reducing effect of deltorphin II was eliminated by administration of chelerythrine (a protein kinase C (PKC) inhibitor), glibenclamide (a KATP-channels inhibitor), and 5-hydroxydecanoate (a mitochondrial KATP-channel blocker). Administration of other opioids did not reduce the IS/AAR index. It has been established that all the deltorphins manifest antiarrhythmic potency. Other opioids do not produce any effect on the incidence of arrhythmia occurrences. The antiarrhythmic effect of deltorphin II was eliminated by preliminary administration of naltrexone, naloxone methiodide, and naltriben, but BNTX did not affect the δ2-agonist's anti-arrhythmic effect. The preliminary administration of chelerythrine, a PKC inhibitor, eliminated the δ2 agonist's antiarrhythmic action. However, glibenclamide and 5-hydroxydecanoate did not alter the antiarrhythmic effect by deltorphin II. Therefore, activation of the peripheral δ2-ORs reduces the infarct size and prevents the onset of arrhythmias. The antiarrhythmic effect of the δ2-OR stimulation is mediated by activating PKC and opening the mitochondrial KATP-channels. PKC participates in the antiarrhythmic effect of the δ2-OR activation, but this effect does not depend on the condition of KATP-channels.",
author = "Lishmanov, {Yu B.} and Maslov, {L. N.} and Barzakh, {E. I.} and Krylatov, {A. V.} and Oltgen, {P. R.} and Browne, {S. A.} and M. Govindashvami",
year = "2009",
month = "7",
day = "1",
doi = "10.1134/S1062359009040062",
language = "English",
volume = "36",
pages = "354--362",
journal = "Biology Bulletin",
issn = "1062-3590",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "4",

}

TY - JOUR

T1 - Effects of activation of μ-, κ1-, δ1-, δ2-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusion

AU - Lishmanov, Yu B.

AU - Maslov, L. N.

AU - Barzakh, E. I.

AU - Krylatov, A. V.

AU - Oltgen, P. R.

AU - Browne, S. A.

AU - Govindashvami, M.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Different subtypes of opioid receptors (OR) were activated in rats in vivo to study the activation effect on the heart's resistance to ischemia and reperfusion. It has been established that administration of deltorphin II, a selective δ2-OR agonist, lowered the infarct size/area at risk index (IS/AAR) by 23%. Naltrexone, naloxone methiodide (an OR inhibitor not penetrating the blood-brain barrier (BBB)), and naltriben (δ2-antagonist) eliminated the cardioprotective effect of deltorphin II, while BNTX (a δ1-antagonist) produced no effect on the cardioprotective action of the δ2-agonist. The infarct-reducing effect of deltorphin II was eliminated by administration of chelerythrine (a protein kinase C (PKC) inhibitor), glibenclamide (a KATP-channels inhibitor), and 5-hydroxydecanoate (a mitochondrial KATP-channel blocker). Administration of other opioids did not reduce the IS/AAR index. It has been established that all the deltorphins manifest antiarrhythmic potency. Other opioids do not produce any effect on the incidence of arrhythmia occurrences. The antiarrhythmic effect of deltorphin II was eliminated by preliminary administration of naltrexone, naloxone methiodide, and naltriben, but BNTX did not affect the δ2-agonist's anti-arrhythmic effect. The preliminary administration of chelerythrine, a PKC inhibitor, eliminated the δ2 agonist's antiarrhythmic action. However, glibenclamide and 5-hydroxydecanoate did not alter the antiarrhythmic effect by deltorphin II. Therefore, activation of the peripheral δ2-ORs reduces the infarct size and prevents the onset of arrhythmias. The antiarrhythmic effect of the δ2-OR stimulation is mediated by activating PKC and opening the mitochondrial KATP-channels. PKC participates in the antiarrhythmic effect of the δ2-OR activation, but this effect does not depend on the condition of KATP-channels.

AB - Different subtypes of opioid receptors (OR) were activated in rats in vivo to study the activation effect on the heart's resistance to ischemia and reperfusion. It has been established that administration of deltorphin II, a selective δ2-OR agonist, lowered the infarct size/area at risk index (IS/AAR) by 23%. Naltrexone, naloxone methiodide (an OR inhibitor not penetrating the blood-brain barrier (BBB)), and naltriben (δ2-antagonist) eliminated the cardioprotective effect of deltorphin II, while BNTX (a δ1-antagonist) produced no effect on the cardioprotective action of the δ2-agonist. The infarct-reducing effect of deltorphin II was eliminated by administration of chelerythrine (a protein kinase C (PKC) inhibitor), glibenclamide (a KATP-channels inhibitor), and 5-hydroxydecanoate (a mitochondrial KATP-channel blocker). Administration of other opioids did not reduce the IS/AAR index. It has been established that all the deltorphins manifest antiarrhythmic potency. Other opioids do not produce any effect on the incidence of arrhythmia occurrences. The antiarrhythmic effect of deltorphin II was eliminated by preliminary administration of naltrexone, naloxone methiodide, and naltriben, but BNTX did not affect the δ2-agonist's anti-arrhythmic effect. The preliminary administration of chelerythrine, a PKC inhibitor, eliminated the δ2 agonist's antiarrhythmic action. However, glibenclamide and 5-hydroxydecanoate did not alter the antiarrhythmic effect by deltorphin II. Therefore, activation of the peripheral δ2-ORs reduces the infarct size and prevents the onset of arrhythmias. The antiarrhythmic effect of the δ2-OR stimulation is mediated by activating PKC and opening the mitochondrial KATP-channels. PKC participates in the antiarrhythmic effect of the δ2-OR activation, but this effect does not depend on the condition of KATP-channels.

UR - http://www.scopus.com/inward/record.url?scp=71449084822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71449084822&partnerID=8YFLogxK

U2 - 10.1134/S1062359009040062

DO - 10.1134/S1062359009040062

M3 - Article

VL - 36

SP - 354

EP - 362

JO - Biology Bulletin

JF - Biology Bulletin

SN - 1062-3590

IS - 4

ER -